Filing Flows › Xeris Biopharma Holdings (XERS) › Guidance & outlook
Xeris Biopharma Holdings (XERS) guidance and outlook
Xeris Biopharma Holdings (XERS) raised its guidance on Nov 5, 2026: Revenue $395M–$405M for FY2026; Revenue $1.0B for FY2030. Xeris Biopharma Holdings' 10-Q filed Nov 5, 2026 makes 7 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $395M–$405M | raised |
| Revenue | FY2030 | $1.0B | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We are working with the United States Food and Drug Administration ("FDA") and plan to initiate a Phase 3 clinical trial of our XP-8121 product candidate.
- We believe this will generate value to all of our stakeholders.
- Patent No. 12,758,502, which relates to Keveyis and which we expect to provide patent protection through at least 2039.
- There can be no assurance that such funding may be available to us on acceptable terms, or at all, or that we will be able to commercialize our product candidates, if approved.
- We track external research and development costs by project, however, personnel related expenses related to research and development are not allocated by project.
- We expect to continue to incur significant research and development expenses as we advance our pipeline candidates and in particular plan and conduct clinical trials, prepare regulatory filings for our product candidates, and utilize internal resources to support these efforts.
- As detailed in the section titled "Financing" included in "Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations" of Part I of this Quarterly Report, there can be no assurance that such funding may be available to us on acceptable terms, or at all, or that we will be able to successfully market and sell Recorlev, Gvoke and Keveyis.
Xeris Biopharma Holdings' latest quarter
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did Xeris Biopharma Holdings raise or lower its guidance?
Xeris Biopharma Holdings (XERS) raised its guidance on Nov 5, 2026: Revenue $395M–$405M for FY2026; Revenue $1.0B for FY2030.
What does Xeris Biopharma Holdings expect?
We are working with the United States Food and Drug Administration ("FDA") and plan to initiate a Phase 3 clinical trial of our XP-8121 product candidate. We believe this will generate value to all of our stakeholders. Patent No. 12,758,502, which relates to Keveyis and which we expect to provide patent protection through at least 2039.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.